drugset / Trial / NCT04821310

Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years

NCT04821310

Phase 2 Terminated 43 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to explore the outcomes, tolerability and safety of 2 different doses of oral pantoprazole (full healing dose, half healing dose), assigned based upon weight, for the maintenance of healing of erosive esophagitis in pediatric participants aged 1 to 17 years with endoscopically-confirmed, healed erosive esophagitis.

Timeline

Start
2022-01-13
Primary completion
2025-12-16
Completion
2025-12-16

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pantoprazole Other / unclassified Oral

Indications